Cytokinetics, Incorporated (CYTK)

業務介紹

Cytokinetics, Incorporated（Cytokinetics公司）是一家後期階段的生物製藥公司，專注於發現、開發和商業化肌肉活化劑和抑制劑，作為治療嚴重疾病的潛在方法。該公司主要開發小分子藥物候選，旨在影響肌肉功能和收縮能力。其藥物候選包括omecamtiv mecarbil，一種新型心肌肌球蛋白活化劑，目前正在進行心力衰竭患者的III期臨床試驗；以及reldesemtiv，一種骨骼肌肌鈣蛋白活化劑，目前正在進行治療肌萎縮性脊髓側索硬化症和脊髓性肌肉萎縮症的III期臨床試驗。該公司還開發了CK-136，一種新型心肌肌鈣蛋白活化劑，目前正在進行I期臨床試驗；aficamten，一種新型心肌肌球蛋白抑制劑，目前正在進行對症治療有症狀的梗阻性肥厚型心肌病患者的III期臨床試驗；以及CK-3772271，一種小分子心肌肌球蛋白抑制劑，目前正在進行I期臨床試驗。Cytokinetics, Incorporated與Astellas Pharma Inc.有戰略聯盟關係。該公司成立於1997年，總部位於加利福尼亞州南舊金山。

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

公司網址

https://www.cytokinetics.com